

Applicant : Paul R. Odgren, et al.
Serial No. : 09/933,915
Filed : August 20, 2001
Page : 3

Attorney's Docket No. 07917-120001 / UMMc 00-34
Trance

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and correct typographical errors in the specification.

Further, new Figure 2 has been substituted for the original Figure 2. This amendment has been made because the original Figure 2 was a duplication of Figure 4. New Figure 2 properly depicts the deduced amino acid sequence of SEQ ID NO:1. As recited in the Brief Description of the Drawings, the amino acid sequence in new Figure 2 is depicted in the GenBank database as Accession No. NM_003701. Thus, no new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

November 13, 2001

J. Peter Fasse

J. Peter Fasse
Reg. No. 32,983

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Version With Markings to Show Changes Made

In the specification:

Paragraph beginning at page 8, line 1, has been amended as follows:

For example, human TRANCE antisense oligonucleotides that consist of 24 to 50 nucleotides encompassing the translation initiation codon can be used to inhibit TRANCE activity. In Homo sapiens tumor necrosis factor (ligand) superfamily, member 11 (TNFSF11), mRNA splice variant 1 (GenBank Accession # NM_003701.2), this would include the region from nucleotides 141 to 190 (SEQ ID NO:17)[], including the start codon at nucleotide number 157 (see FIG. 1). In mRNA splice variant 2 (GenBank Accession # []NM_033012.1), this would include nucleotides 81 to [131] 140 (SEQ ID NO:18), including the start codon at nucleotide number 95 (see FIG. 3).